Valeant Clears Decks, Ups Offer For Allergan – And Says B&L Offers Good Blueprint For Integration
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.